Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck ups Spanish drug capacity 50%
by Alex Scott
October 24, 2016
| A version of this story appeared in
Volume 94, Issue 42
Merck KGaA has increased its biotech drug production capacity in Spain by 50% by expanding its facility in Tres Cantos, near Madrid, at a cost of $16 million. As part of the project, the German firm has increased staffing at the site by 20% to 170. Tres Cantos is Merck’s primary location for producing the active substances for the fertility treatment Gonal-f and growth hormone disorder treatment Saizen. Merck says it has invested about $275 million in health care manufacturing during 2016.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter